$35.81 Million in Sales Expected for Nektar Therapeutics (NKTR) This Quarter

Equities research analysts expect that Nektar Therapeutics (NASDAQ:NKTR) will report sales of $35.81 million for the current quarter, Zacks reports. Three analysts have made estimates for Nektar Therapeutics’ earnings. The highest sales estimate is $41.09 million and the lowest is $28.43 million. Nektar Therapeutics posted sales of $37.45 million in the same quarter last year, which suggests a negative year over year growth rate of 4.4%. The firm is expected to report its next earnings report on Wednesday, March 7th.

According to Zacks, analysts expect that Nektar Therapeutics will report full year sales of $35.81 million for the current fiscal year, with estimates ranging from $240.68 million to $253.34 million. For the next fiscal year, analysts forecast that the business will post sales of $202.66 million per share, with estimates ranging from $161.08 million to $252.10 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that follow Nektar Therapeutics.

A number of analysts have recently issued reports on the stock. BidaskClub cut shares of Nektar Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday. Mizuho increased their price objective on shares of Nektar Therapeutics from $45.00 to $89.00 and gave the stock a “buy” rating in a research note on Monday, January 22nd. Zacks Investment Research raised shares of Nektar Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, January 16th. Jefferies Group increased their price objective on shares of Nektar Therapeutics from $2.12 to $88.00 and gave the stock a “buy” rating in a research note on Tuesday, January 16th. Finally, Canaccord Genuity reissued a “buy” rating and issued a $80.00 price objective (up from $50.00) on shares of Nektar Therapeutics in a research note on Wednesday, January 10th. Three research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $46.17.

In related news, Director Christopher A. Kuebler sold 30,000 shares of the firm’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $58.66, for a total transaction of $1,759,800.00. Following the completion of the transaction, the director now directly owns 70,500 shares of the company’s stock, valued at $4,135,530. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Howard W. Robin sold 83,333 shares of the firm’s stock in a transaction on Monday, January 22nd. The shares were sold at an average price of $75.82, for a total transaction of $6,318,308.06. Following the transaction, the chief executive officer now directly owns 333,268 shares of the company’s stock, valued at $25,268,379.76. The disclosure for this sale can be found here. Insiders have sold 196,666 shares of company stock valued at $12,718,923 over the last ninety days. 5.44% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of NKTR. Nationwide Fund Advisors grew its stake in Nektar Therapeutics by 30.1% during the second quarter. Nationwide Fund Advisors now owns 107,555 shares of the biopharmaceutical company’s stock valued at $2,103,000 after acquiring an additional 24,875 shares in the last quarter. New York State Common Retirement Fund grew its stake in Nektar Therapeutics by 38.0% during the second quarter. New York State Common Retirement Fund now owns 277,184 shares of the biopharmaceutical company’s stock valued at $5,419,000 after acquiring an additional 76,356 shares in the last quarter. California Public Employees Retirement System grew its stake in Nektar Therapeutics by 2.2% during the second quarter. California Public Employees Retirement System now owns 190,900 shares of the biopharmaceutical company’s stock valued at $3,732,000 after acquiring an additional 4,100 shares in the last quarter. Parametric Portfolio Associates LLC grew its stake in Nektar Therapeutics by 30.6% during the second quarter. Parametric Portfolio Associates LLC now owns 325,501 shares of the biopharmaceutical company’s stock valued at $6,364,000 after acquiring an additional 76,350 shares in the last quarter. Finally, Voya Investment Management LLC lifted its position in Nektar Therapeutics by 20.1% during the second quarter. Voya Investment Management LLC now owns 68,910 shares of the biopharmaceutical company’s stock valued at $1,347,000 after purchasing an additional 11,538 shares during the last quarter. 96.00% of the stock is owned by institutional investors.

Shares of Nektar Therapeutics (NASDAQ NKTR) opened at $74.64 on Monday. The company has a debt-to-equity ratio of 2.91, a quick ratio of 3.99 and a current ratio of 4.14. Nektar Therapeutics has a 52 week low of $12.50 and a 52 week high of $99.02.

WARNING: This story was reported by American Banking News and is owned by of American Banking News. If you are reading this story on another website, it was copied illegally and reposted in violation of US and international copyright & trademark legislation. The original version of this story can be accessed at https://www.americanbankingnews.com/2018/02/12/35-81-million-in-sales-expected-for-nektar-therapeutics-nktr-this-quarter.html.

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Get a free copy of the Zacks research report on Nektar Therapeutics (NKTR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply